The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K

Dedicated to the memory of Dr. Gideon Rodan, deceased, January 1, 2006
https://doi.org/10.1016/j.bmcl.2007.12.047Get rights and content

Abstract

Odanacatib is a potent, selective, and neutral cathepsin K inhibitor which was developed to address the metabolic liabilities of the Cat K inhibitor L-873724. Substituting P1 and modifying the P2 side chain led to a metabolically robust inhibitor with a long half-life in preclinical species. Odanacatib was more selective in whole cell assays than the published Cat K inhibitors balicatib and relacatib. Evaluation in dermal fibroblast culture showed minimal intracellular collagen accumulation relative to less selective Cat K inhibitors.

References and notes (21)

  • P. Saftig et al.

    Proc. Natl. Acad. Sci.

    (1998)
  • S. Kumar et al.

    Bone

    (2007)
  • S. Adami et al.

    J. Bone Min. Res.

    (2006)
  • C.S. Li et al.

    Bioorg. Med. Chem. Lett.

    (2006)
  • J.P. Falgueyret et al.

    Anal. Biochem.

    (2004)
  • V. Everts et al.

    Histochem. J.

    (1996)
  • U.B. Grabowska et al.

    Curr. Opin. Drug Discovery Dev.

    (2005)
    R.W. Marquis

    Ann. Rep. Med. Chem.

    (2004)
  • D.G. Barrett et al.

    Bioorg. Med. Chem. Lett.

    (2005)
  • J. Robichaud et al.

    J. Med. Chem.

    (2003)
There are more references available in the full text version of this article.

Cited by (407)

View all citing articles on Scopus
View full text